| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
53 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-277 |
| Cash Flow (TTM) (Millions $) |
430 |
| Capital Exp. (TTM) (Millions $) |
17 |
Business Description
Myokardia Inc is a biopharmaceutical company that focuses on developing targeted therapies for the treatment of genetic cardiovascular diseases. The company's primary focus is on developing small molecule therapeutics that can address the underlying causes of cardiovascular conditions such as hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
Myokardia's approach involves researching and targeting specific genes and proteins that play a role in cardiac muscle function and regulation. By understanding the genetic and molecular basis of these diseases, the company aims to develop innovative and personalized therapies that can improve outcomes for patients.
The company's lead product candidate is Mavacamten, which is being developed as a potential treatment for HCM. Mavacamten works by inhibiting the excess contractility of the heart muscle, which is a characteristic feature of HCM. Clinical trials have shown promising results, with potential for improving symptoms, exercise capacity, and overall quality of life in patients with HCM.
In addition to Mavacamten, Myokardia is also exploring other potential therapies for various cardiovascular diseases, including DCM. The company's ultimate goal is to provide effective and targeted treatments for patients with genetic cardiovascular diseases, reducing the burden of these conditions and improving patient outcomes.
Company Address: 1000 Sierra Point Parkway Brisbane 94005 CA
Company Phone Number: 741-0900 Stock Exchange / Ticker: NASDAQ MYOK
|
%